0.431
0.99%
-0.0043
After Hours:
.412
-0.019
-4.41%
Soligenix Inc stock is currently priced at $0.431, with a 24-hour trading volume of 1.01M.
It has seen a -0.99% decreased in the last 24 hours and a -30.60% declined in the past month.
The chart indicates a potential bearish trend, as the stock is below the $0.4381 pivot point. If it approaches the $0.4082 support level, significant changes may occur.
Soligenix Inc Stock (SNGX) Financials Data
Soligenix Inc (SNGX) Revenue 2024
SNGX reported a revenue (TTM) of $960.60 thousand for the quarter ending September 30, 2023, a +11.89% rise year-over-year.
Soligenix Inc (SNGX) Net Income 2024
SNGX net income (TTM) was -$6.14 million for the quarter ending December 31, 2023, a +55.50% increase year-over-year.
Soligenix Inc (SNGX) Cash Flow 2024
SNGX recorded a free cash flow (TTM) of -$8.60 million for the quarter ending December 31, 2023, a +32.05% increase year-over-year.
Soligenix Inc (SNGX) Earnings per Share 2024
SNGX earnings per share (TTM) was -$0.90 for the quarter ending December 31, 2023, a +81.29% growth year-over-year.
Soligenix Inc Stock (SNGX) Latest News
Why Alcoa Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket
Benzinga
Don’t Trade Penny Stocks Until You’ve Taken These Steps
PennyStocks
S&P 500 Down Over 1%; US Retail Sales Increase 0.7% In March
Benzinga
Why Ultragenyx Pharmaceutical Shares Are Trading Lower By Around 9%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Benzinga
Crude Oil Down 1%; Charles Schwab Sales Top Estimates
Benzinga
Dow Jumps Over 300 Points; Goldman Sachs Posts Upbeat Earnings
Benzinga
About Soligenix Inc
Soligenix, Inc., a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States. It operates in two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301 (HyBryte), a novel photodynamic therapy, which has completed Phase III clinical trial for the treatment of treat cutaneous T-cell lymphoma; and SGX942, an innate defense regulator technology that is in Phase III clinical trial for the treatment of inflammatory diseases, including oral mucositis in head and neck cancer. This segment also offers proprietary formulations of oral beclomethasone 17,21-dipropionate for the prevention/treatment of gastrointestinal disorders characterized by severe inflammation, including SGX203 for pediatric Crohn's disease; and SGX302 that is in Phase I/II clinical trial for the treatment of mild-to-moderate psoriasis. The Public Health Solutions segment is involved in the development of RiVax, a ricin toxin vaccine candidate, which has completed Phase Ia and Ib clinical trials; SGX943, a therapeutic candidate that is in pre-clinical stage for the treatment of antibiotic resistant and emerging infectious diseases; ThermoVax, a technology in pre-clinical development for thermostabilizing vaccines; and CiVax, a vaccine candidate in pre-clinical development for the prevention of COVID-19. The company was formerly known as DOR BioPharma, Inc. and changed its name to Soligenix, Inc. in 2009. Soligenix, Inc. was incorporated in 1987 and is headquartered in Princeton, New Jersey.
Cap:
|
Volume (24h):